PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer

• Published in: Scientific reports Vol. 14; no. 1; pp. 15307 - 11
• Main Authors: Sakamoto, Shinichi, Sato, Kodai, Kimura, Takahiro, Matsui, Yoshiyuki, Shiraishi, Yusuke, Hashimoto, Kohei, Miyake, Hideaki, Narita, Shintaro, Miki, Jun, Matsumoto, Ryuji, Kato, Takuma, Saito, Toshihiro, Tomida, Ryotaro, Shiota, Masaki, Joraku, Akira, Terada, Naoki, Suekane, Shigetaka, Kaneko, Tomoyuki, Tatarano, Shuichi, Yoshio, Yuko, Yoshino, Takayuki, Nishiyama, Naotaka, Kawakami, Eiryo, Ichikawa, Tomohiko, Kitamura, Hiroshi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03.07.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/409; 692/4025/1752; Aged; Aged, 80 and over; Antigens; Castration; East Asian People; Humanities and Social Sciences; Humans; Japan - epidemiology; Male; Medical prognosis; Middle Aged; multidisciplinary; NHT; nmCRPC; Prognosis; Prostate cancer; Prostate-specific antigen; Prostate-Specific Antigen - blood; Prostatic Neoplasms, Castration-Resistant - blood; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - mortality; Prostatic Neoplasms, Castration-Resistant - pathology; PSA doubling time; Science; Science (multidisciplinary); Survival; Vintage; Japan; NHT; nmCRPC; Prostate cancer; PSA doubling time; Vintage
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-65969-3

A multicenter study of nonmetastatic castration-resistant prostate cancer (nmCRPC) was conducted to identify the optimal cut-off value of prostate-specific antigen (PSA) doubling time (PSADT) that correlated with the prognosis in Japanese nmCRPC. Of the 515 patients diagnosed and treated for nmCRPC at 25 participating Japanese Urological Oncology Group centers, 450 patients with complete clinical information were included. The prognostic values of clinical factors were evaluated with respect to prostate specific antigen progression-free (PFS), cancer-specific survival (CSS), and overall survival (OS). The optimal cutoff value of PSADT was identified using survival tree analysis by Python. The Median PSA and PSADT at diagnosis of nmCRPC were 3.3 ng/ml, and 5.2 months, respectively. Patients treated with novel hormonal therapy (NHT) showed significantly longer PFS (HR: hazard ratio 0.38, p < 0.0001) and PFS2 (HR 0.45, p < 0.0001) than those treated with vintage nonsteroidal antiandrogen agent (Vintage). The survival tree identified 4.65 months as the most prognostic PSADT cutoff point. Among the clinical and pathological factors PSADT of < 4.65 months remained an independent prognostic factor for OS (HR 2.96, p = 0.0003) and CSS (HR 3.66, p < 0.0001). Current data represented optimal cut-off of PSADT 4.65 months for a Japanese nmCRPC.